Vascular targeting agents

Combretastatin A4 phosphate (72) is a phosphate prodrug of combretastatin A4, a c/s-stilbene, isolated from Combretum caffrum (66). Combretastatin A4 is one of the many combretas-tatins that inhibits tubulin polymerization (67), shows efficacy against solid tumor, is a vascular targeting agent that blocks the blood supply to solid tumors, and is in Phase II/III clinical development for the treatment of various types of tumors as a vascular targeting agent (68-71). 

ZD-6126 N-Acetyl-colchinol-phosphate (le) Phase II ongoing n.p. Astra Zeneca vascular targeting agent [22,23]... 

CA4P (Prodrug) (5c) Phase II 0.9-3 nM (drug) Oxigene INC vascular targeting agent [30,34,36 37]... 

Tozer GM, Prise VE, Wilson J, Locke RJ, Vojnovic B, Stratford MRL. Combretastatin A-4 phosphate as a tumor vascular-targeting agent Early effects in tumors and normal tissues. Cancer Res 1999 59 1626-1634. 

Gregorc, V., Santoro, A., BenniceUi, E., Punt, C. J., Citterio, G., Timmer-Bonte, J. N., CaUgaris Cappio, F., Lambiase, A., Bordignon, C., and Van Herpen, C. M. 2009. Phase lb study of Ngr-htnf, a selective vascular targeting agent, administered at low doses in combination with doxorubicin to patients with advanced solid tumours. British Journal of Cancer, 101,219-224. 

---